Centogene N.V. (CNTG)
| Market Cap | 252.50M |
| Revenue (ttm) | 54.81M |
| Net Income (ttm) | -23.21M |
| Shares Out | 19.86M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $11.65 |
| Previous Close | $11.55 |
| Change ($) | 0.10 |
| Change (%) | 0.87% |
| Day's Open | 11.85 |
| Day's Range | 11.45 - 12.14 |
| Day's Volume | 113,035 |
| 52-Week Range | 9.30 - 25.16 |
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare dis...
Seeking Alpha Transcripts | Healthcare Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript Dec. 16, 2020 2:58 PM ET | | About: Centogene N.V. (CNTG) by: SA Tr...
Shares of Centogene (NASDAQ:CNTG) remained unaffected in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 97.88% year over year to ($0.30)...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare dis...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wor...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...
Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries Expanded Partnersh...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world cli...
GENT, Belgium and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that tr...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and BAARN, the Netherlands, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare disease...
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-...
Centogene N.V. (CNTG) CEO Arndt Rolfs on Q2 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare ...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...
CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announc...
CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases th...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clin...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 23, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world c...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare d...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announce...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
CAMBRIDGE, Mass. and SANTA MONICA, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 02, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
Centogene (CNTG) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Shares of German genetic diagnosis company Centogene NV (NASDAQ: CNTG) were advancing strongly Monday.
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 29, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world c...
Cambridge, Mass. and ROSTOCK, Germany and BERLIN, June 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
Centogene N.V. (CNTG) CEO Arndt Rolfs on Q1 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-wo...
CAMBRIDGE, Mass. and BERLIN and ROSTOCK, Germany, May 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-worl...
CAMBRIDGE, Mass., USA, ROSTOCK, Germany and BERLIN, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transfo...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 08, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world cl...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 06, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world cl...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,, May 05, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world c...
Centogene N.V. (CNTG) CEO on Arndt Rolfs Q4 2019 Results - Earnings Call Transcript
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 21, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world ...
ROSTOCK, Germany and COLOGNE, Germany, April 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical an...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, April 15, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms re...
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, March 18, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms r...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-w...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its ...
About CNTG
Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidem... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 7, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol CNTG |
Financial Performance
In 2019, Centogene's revenue was 48.78 million, an increase of 20.51% compared to the previous year's 40.48 million. Losses were -20.66 million, 88.3% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Centogene stock is "Strong Buy." The 12-month stock price forecast is 20.84, which is an increase of 78.88% from the latest price.